References
- Klein JO, Remington JS. Current concepts of infections of the fetus and newborn infants. In: Remington JS, Klein JO (eds) Textbook of Infectious Diseases of the Fetus and Newborn In-fant. 51h ed. Philadelphia, PEN: W.B. Saunders Company: pp. 1-23.
- Kaftan H, Kinney JS. Early onset neonatal bacterial infec-tions. Semin Perinatol 1998; 22: 15–24.
- Jeffrey S, Gerdes MD. Diagnosis and management of bac-terial infections in the neonate. Pediatr Clin North Am 2004; 51: 939–959.
- de Hoog M, Mouton JW, van den Anker JN. New dosing strategies for antibacterial agents in the neonate. Semin Fet Neonat Med 2005; 10: 185–194.
- Heimann GG. Enteral absorption and bioavailability in chil-dren in relation to age. Eur J Clin Pharmacol 1980; 18: 43–50.
- Hendrickson JR, North DS. Pharmacoeconomic benefit of antibiotic step-down therapy: converting patients from intra-venous ceftriaxone to oral cefpodoxime proxetil. Ann Pharma-cother 1995; 29: 561–565.
- Vogtlander NP, Van Kasteren ME, Natsch S, Kullberg BJ, Hekster YA, Van der Meer JW. Improving the process of antibi-otic therapy in daily practice: interventions to optimize timing, dosage adjustment to renal function, and switch therapy. Arch Intern Med 2004; 164: 1206–1212.
- Dagan R, Syrogiannopoulos G, Ashkenazi S, Engelhard D, Einhorn M, Gatzola-Karavelli M, et al. Parenteral-oral switch in the management of paediatric pneumonia. Drugs 1994; 47 Suppl 3: 43–51.
- Gollin G, Abarbanell A, Moores D. Oral antibiotics in the management of perforated appendicitis in children. Am Surg 2002; 68: 1072–1074.
- Frampton JE, Brogden RN, Langtry HD, Buckley MM. Cefpodoxime proxetil. A review of its antibacterial activity, phar- macokinetic properties and therapeutic potential. Drugs 1992; 44: 889–917.
- Fulton B, Perry CM. Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric pa-tients. Paediatr Drugs 2001; 3: 137–158.
- Richardson DK, Corcoran JD, Escobar GJ, Lee SK, for the Canadian NICU Network, The Kaiser Permanente Neonatal Minimum Data Set Wide Area Network, The SNAP-II Study Group. SNAP-II and SNAPPE-II: simplified newborn illness sever-ity and mortality risk scores. J Pediatr 2001; 138: 92–100.
- Gras-Le Guen C, Boscher C, Godon N, Caillon J, Nguyen JM, Kergueris MF, et al. Therapeutic amoxicillin levels achieved with oral administration in term neonates. Eur J Clin Pharmacol 2007; 63: 657–662.
- Chirico G, Cortinovis S, Fonte C, Giudici G. Bacterial sep-sis. J Chemother 2007; 19 Suppl. 2: 28-30.
- Allegaert K, Verbesselt R, Naulaers G, van den Anker M, Debeer A, de Hoon J. Developmental pharmacology: neonates are not just small adults. Acta Clin Belg 2008; 63: 16–24.
- Kearns GL, Abdel-Rahman SM, Jacobs RF. Cefpodoxime pharmacokinetics in children: effect of food. Pediatr Infect Dis J 1998; 17: 799–804.
- Carrillo NA, Giguère S, Gronwall RR, Brown MP, Merritt KA, O'Kelley JJ. Disposition of orally administered cefpodoxime proxetil in foals and adult horses and minimum inhibitory con-centration of the drug against common bacterial pathogens of horses. Am J Vet Res 2005; 66: 30–35.
- Bonin MT, Ferry JJ, Forbes KK, Hughes GS. Pharmaco-kinetics of cefpodoxime proxetil in healthy young and elderly vol-unteers. J Clin Pharmacol 1994; 34: 774–781.
- Tremblay D, Dupront A, Ho C, Coussediere D, Lenfant B. Pharmacokinetics of cefpodoxime in young and elderly volun-teers after single doses. J Antimicrob Chemother. 1990; 26 Suppl E: 21-28.
- Borin MT, Hughes GS, Patel RK, Royer ME, Cathcart KS. Pharmacokinetic and tolerance studies of cefpodoxime after sin-gle- and multiple-dose oral administration of cefpodoxime prox-etil. J Clin Pharmacol 1991; 31: 1137–1145.
- Brown SA, Boucher JF, Hubbard VL, Prough MJ, Rook TF. The comparative plasma pharmacokinetics of intravenous cefpodoxime sodium and oral cefpodoxime proxetil in beagle dogs. J Vet Pharmacol Ther 2007; 30: 320–326.